Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the interictal EEG in rats

Cannabinoid CB1 antagonists have been investigated for possible treatment of e.g. obesity-related disorders. However, clinical application was halted due to their symptoms of anxiety and depression. In addition to these adverse effects, we have shown earlier that chronic treatment with the CB1 antag...

Descripción completa

Detalles Bibliográficos
Autores principales: Perescis, Martin F. J., de Bruin, Natasja, Heijink, Liesbeth, Kruse, Chris, Vinogradova, Lyudmila, Lüttjohann, Annika, van Luijtelaar, Gilles, van Rijn, Clementina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289424/
https://www.ncbi.nlm.nih.gov/pubmed/28151935
http://dx.doi.org/10.1371/journal.pone.0165363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289424/
https://www.ncbi.nlm.nih.gov/pubmed/28151935
http://dx.doi.org/10.1371/journal.pone.0165363

Ejemplares similares